Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BSX reports Tuesday with the sharpest insider-versus-analyst split in its recent history, three days before a print that will either validate the executive buying or confirm the sell-side's more cautious read.
The most striking pre-earnings data point is the CEO's open-market purchase. Michael Mahoney bought 186,240 shares at $48.33 in early August, spending $9 million in a single discretionary transaction with no 10b5-1 plan attached. That trade is now underwater: the stock closed Friday at $44.39, down roughly 8% from his entry price. Two directors and the CFO also made open-market or reported purchases across August, collectively adding to a 90-day net insider buy of roughly $9.5 million across all transactions. Discretionary purchases at this scale, by the CEO in particular, are one of the cleaner conviction signals in corporate filings.
Analysts have drawn the opposite conclusion. The trend in sell-side coverage has been consistently lower targets and, in two cases, outright downgrades. Citigroup cut its rating to Neutral in September and trimmed its target again in early October. Truist, still carrying a Buy, cut its target from $57 to $51 on October 14. Barclays initiated at Equal-Weight with a $48 target. The consensus mean price target is $59.24, which implies around 33% upside from current levels, but that figure is anchored by holdouts at the bullish end. The direction of travel is clearly downward. EPS momentum ranks in the 18th percentile on a 90-day basis, and forward earnings estimates are running roughly 22% below year-earlier levels. The bull case rests on AFib market expansion, a global opportunity bulls project growing from $9 billion to $15 billion by 2028, and procedure volume growth of 5% to 10% following recent trial results. Bears point to market share erosion in radiofrequency and cryoablation, pricing pressure, and a debt load that limits financial flexibility.
Options positioning has also turned more defensive into the print. The put/call ratio moved to 0.50 on Thursday, more than two standard deviations above its 20-day average of 0.43. That is the most cautious options skew BSX has shown in the recent period, even as the stock gained 3.9% on the week. The lending market offers no supporting signal for bears: availability is effectively unlimited, with over 1.4 billion shares available to borrow, and the cost to borrow sits at just 0.36%. Short interest at 2.9% of the free float is modest and not the primary market conversation.
One angle that goes beyond the print itself is the index rebalance picture. ORTEX puts an 80% probability on a BSX share-count increase in the S&P 500, tied to the agreed Penumbra acquisition, with an estimated $387 million of passive buying required around November 27. A separate CRSP US Mid increase carries a 75% probability and a further $622 million in forecast flows around the December quarterly review. These are ORTEX forecasts, not confirmed announcements, and the dates are estimated. But the potential scale, close to $1 billion in mechanically driven buying if both proceed, is a structural tailwind that sits independently of Tuesday's print.
The earnings report will test whether the company's underlying procedure volumes and margin trajectory match the conviction shown by executives who spent real money in the $47 to $49 range, or whether the analysts steadily trimming targets since July have the better read on where 2026 numbers are landing.
See the live data behind this article on ORTEX.
Open BSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
